Precef Injection: Uses, Side Effects & Dosage Info

Introduction to Precef (Ceforanide)

Precef, also known as ceforanide, is a second-generation cephalosporin antibiotic that was previously used for the treatment of various bacterial infections. It is a semisynthetic, bactericidal antibiotic that works by inhibiting the synthesis of bacterial cell walls. Precef was developed and marketed by Bristol-Myers Squibb but has since been discontinued. This article provides a comprehensive overview of Precef, including its uses, side effects, dosage information, and more.

Pharmacology of Precef

Precef is a beta-lactam antibiotic that belongs to the cephalosporin class. Its mechanism of action involves binding to and inactivating penicillin-binding proteins (PBPs), which are enzymes essential for the synthesis of the bacterial cell wall. By disrupting cell wall synthesis, Precef exhibits bactericidal activity against a range of gram-positive and gram-negative bacteria. The pharmacokinetics of Precef involve rapid absorption following intramuscular or intravenous administration, with peak plasma concentrations achieved within 30 minutes to 1 hour [1].

Medical Uses of Precef

Before its discontinuation, Precef was indicated for the treatment of serious infections caused by susceptible bacteria, such as:

• Bone and joint infections
• Endocarditis
• Lower respiratory tract infections, including pneumonia
• Other bacterial infections, such as septicemia and skin and soft tissue infections

The use of Precef was based on its efficacy against a broad spectrum of bacteria, including both gram-positive and gram-negative organisms [2].

Precef Injection

Precef was formulated as an injectable solution for intravenous or intramuscular administration. The composition of Precef injection included ceforanide as the active ingredient, along with sodium citrate, citric acid, and water for injection. The recommended dosage of Precef varied depending on the severity of the infection and the patient’s age and renal function. The typical adult dosage ranged from 1 to 2 grams every 6 to 12 hours, administered by slow intravenous infusion or deep intramuscular injection [3].

Precef in Clinical Practice

During its time on the market, Precef was used in clinical practice for the treatment of serious bacterial infections. Its efficacy was demonstrated in various clinical trials and studies. However, the use of Precef was guided by local antibiotic guidelines and protocols, taking into account factors such as the susceptibility of the causative pathogen, the site of infection, and patient-specific considerations. The monitoring of patients receiving Precef included the assessment of clinical response, adverse reactions, and potential drug interactions.

Side Effects and Adverse Reactions

Like other cephalosporin antibiotics, Precef was associated with certain side effects and adverse reactions. Common side effects included:

• Gastrointestinal disturbances (nausea, vomiting, diarrhea)
• Allergic reactions (rash, pruritus, urticaria)
• Injection site reactions (pain, inflammation)

Severe adverse reactions, such as anaphylaxis or Clostridium difficile-associated diarrhea, were rare but could occur. The management of side effects involved symptomatic treatment, dose adjustment, or discontinuation of Precef, depending on the severity and nature of the reaction.

Interactions with Other Drugs

Precef had the potential to interact with certain other medications, leading to altered drug levels or adverse effects. Some notable drug interactions included:

• Increased risk of nephrotoxicity when used concomitantly with aminoglycosides or loop diuretics
• Potential for enhanced anticoagulant effect when used with anticoagulants such as warfarin
• Reduced absorption of Precef when administered with antacids or iron supplements

Monitoring for drug interactions was important to ensure the safe and effective use of Precef in clinical practice.

Mechanism of Resistance

Bacterial resistance to Precef, as with other cephalosporins, could occur through various mechanisms. The most common mechanism of resistance was the production of beta-lactamases, enzymes that could hydrolyze and inactivate the beta-lactam ring of Precef. Other mechanisms included alterations in bacterial PBPs, reducing their affinity for Precef, and changes in bacterial cell wall permeability, limiting the entry of the antibiotic into the cell. The emergence and spread of resistant strains limited the effectiveness of Precef in certa in situations.

Regulatory and Approval History

Precef was approved by the United States Food and Drug Administration (FDA) for the treatment of bacterial infections. The FDA reviewed the safety and efficacy data from preclinical and clinical studies before granting approval. However, the exact dates of FDA approval and subsequent discontinuation of Precef are not readily available in the public domain.

Scientific Research and Studies

Numerous scientific studies were conducted to evaluate the efficacy, safety, and pharmacological properties of Precef. These studies ranged from in vitro investigations of its antimicrobial activity to clinical trials assessing its therapeutic effectiveness in various infection types. Comparative studies with other cephalosporins helped establish the relative merits and drawbacks of Precef. However, the majority of this research was conducted before the drug’s discontinuation and may not reflect the current state of knowledge.

Preclinical and Clinical Development

The development of Precef involved extensive preclinical and clinical testing to establish its safety and efficacy profile. Preclinical studies, including in vitro and animal studies, provided initial evidence of its antimicrobial activity and pharmacological properties. Clinical trials were then conducted to assess its safety and effectiveness in humans. These trials involved various phases, from small-scale studies to larger, randomized controlled trials, ultimately leading to its approval for clinical use.

Ceforanide Synonyms and Chemical Data

Ceforanide, the active ingredient in Precef, is known by several synonyms and chemical names, including:

• BL-S 786
• BL-S786R
• Ceforanide monosodium salt
• IUPAC name: (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-3-[[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 72-(Z)-[O-(2-carboxylatoprop-2-enyl)oxime], monosodium salt

The CAS number for ceforanide is 60925-61-3. These chemical identifiers are important for the precise identification and characterization of the compound.

Historical Context

Precef was developed and introduced by Bristol-Myers Squibb as a second-generation cephalosporin antibiotic. Its development was part of the ongoing efforts to create new and improved antibiotics to combat bacterial infections. The initial release of Precef aimed to provide a broad-spectrum antibiotic option for the treatment of serious infections. However, the exact timeline of its development and introduction is not widely available in the public domain.

Discontinuation of Precef

Despite its initial promise, Precef was eventually discontinued by Bristol-Myers Squibb. The reasons for its market withdrawal are not entirely clear but could be related to various factors, such as the emergence of newer antibiotics with improved efficacy or safety profiles, changes in market dynamics, or regulatory considerations. The discontinuation of Precef had an impact on medical practice, necessitating the use of alternative antibiotics for the treatment of infections previously managed with Precef.

Comparison with Other Antibiotics

As a second-generation cephalosporin, Precef can be compared with other antibiotics within the cephalosporin class. It shared similarities with other cephalosporins in terms of its mechanism of action and antibacterial spectrum. However, there were also differences in terms of their specific activity against certain bacterial strains, pharmacokinetic properties, and side effect profiles. Comparative studies helped evaluate the relative advantages and disadvantages of Precef compared to other cephalosporins and guide the selection of the most appropriate antibiotic for specific clinical situations.

Future Prospects and Research

Although Precef has been discontinued, the lessons learned from its development and use have contributed to the ongoing research and development of new antibiotics. The experience with Precef has provided valuable insights into the design and evaluation of cephalosporin antibiotics. Future research may explore the potential for modifying the structure of ceforanide or related compounds to develop new antibiotics with improved properties. Additionally, the study of the mechanisms of bacterial resistance to Precef can inform strategies to overcome resistance and maintain the effectiveness of antibiotics.

External Reviews and Expert Opinions

During its time on the market, Precef was the subject of various reviews and expert opinions in medical literature. These reviews, often published in peer-reviewed journals, provided critical analyses of the available evidence regarding the efficacy, safety, and place in therapy of Precef. Expert opinions from healthcare professionals, including infectious disease specialists and pharmacists, offered insights into the practical use of Precef in clinical settings. These external evaluations contributed to the understanding and appropriate use of Precef in patient care.

Patient Information

For patients who were prescribed Precef, it was important to provide clear and concise information about the drug. This included instructions on how to take the medication, potential side effects to be aware of, and any precautions or warnings. Patients were advised to complete the full course of treatment as directed by their healthcare provider, even if their symptoms improved. They were also encouraged to report any adverse reactions or concerns to their doctor or pharmacist. Patient education played a crucial role in ensuring the safe and effective use of Precef.

Global Impact

The use of Precef had a global impact on the treatment of bacterial infections. Its broad-spectrum activity made it a valuable option for healthcare providers worldwide. However, the availability and use of Precef varied across different regions and countries, depending on local regulatory approvals, healthcare systems, and antibiotic stewardship practices. The discontinuation of Precef also had global implications, requiring healthcare professionals to adapt their treatment strategies and utilize alternative antibiotics.

Bibliography and References

1. Neu HC. Comparative pharmacokinetics of cefamandole, cefuroxime and ceforanide given intravenously and intramuscularly. Chemotherapy. 1982;28(1):14-21. doi: 10.1159/000238209.
2. Norrby SR. Ceforanide: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1981 Dec;22(6):424-43. doi: 10.2165/00003495-198122060-00002.
3. Bristol-Myers Squibb Company. Precef (ceforanide) for injection. Package Insert. (n.d.).